OPTIMIZATION OF ONCORETROVIRAL VECTORS ENCODING RNA DECOYS

编码 RNA 诱饵的肿瘤逆转录病毒载体的优化

• 批准号: 7349504
• 负责人: Stephen E. Braun
• 金额: $ 13.48万
• 依托单位: HARVARD MEDICAL SCHOOL
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7349504
• 关键词: OPTIMIZATION; ONCORETROVIRAL; VECTORS; ENCODING; RNA

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. RNA decoys have a number of advantages for the inhibition of HIV replication, including their lack of immunogenicity and their ability to target conserved genes essential for viral replication. However, optimal inhibition of viral replication by RNA decoys has generally been obtained with multimeric RNA decoys, which significantly increase the risk of transgene instability when delivered using retroviral vectors. We therefore examined a number of parameters affecting the ability of oncoretroviral vectors to stably deliver HIV-1 RNA decoys and inhibit viral replication. For the retroviral backbone, we chose the oncoretroviral vector MMP, which does not contain a selectable marker gene, and generated a series of vectors with and without intact splice donor and splice acceptor signals, and with the oncoretroviral LTR or an internal HIV-1 LTR transcriptionally regulating the polymeric TAR and RRE RNA decoys. By decreasing the number of TAR decoys, vector stability was increased, resulting in more efficient inhibition of viral replication in transduced cells. Inclusion of an internal HIV promoter within the retroviral vector provided more consistent viral inhibition. The efficiency of these different vectors has been evaluated in multiple T cell clones derived from transduced cells and stable high titer producer cell lines generated. Transduction of autologous CD34+ bone marrow cells with one of these vectors has resulted in stable gene marking of 0.1 percent - 1 percent of lymphocytes. These optimized vectors will facilitate analysis of the efficacy of RNA decoys for stem cell gene for AIDS in a nonhuman primate model.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。RNA诱饵在抑制HIV复制方面具有许多优势，包括它们缺乏免疫原性和靶向病毒复制所必需的保守基因的能力。然而，RNA诱饵对病毒复制的最佳抑制通常是使用多聚体RNA诱饵，当使用逆转录病毒载体传递时，这显著增加了转基因不稳定的风险。因此，我们研究了一些影响逆转录病毒载体稳定递送HIV-1 RNA诱饵和抑制病毒复制能力的参数。对于逆转录病毒主干，我们选择了不包含可选择标记基因的逆转录病毒载体MMP，并生成了一系列具有和不具有完整剪接供体和剪接受体信号的载体，以及具有逆转录病毒LTR或内部HIV-1 LTR转录调节聚合TAR和RRE RNA诱饵的载体。通过减少TAR诱饵的数量，增加了载体的稳定性，从而更有效地抑制了转导细胞中的病毒复制。在逆转录病毒载体中包含一个内部HIV启动子提供了更一致的病毒抑制。这些不同载体的效率已经在从转导细胞衍生的多个T细胞克隆和稳定的高滴度产生细胞系中进行了评估。用其中一种载体转导自体CD34+骨髓细胞，可以在0.1% - 1%的淋巴细胞中实现稳定的基因标记。这些优化的载体将有助于在非人灵长类动物模型中分析艾滋病干细胞基因RNA诱饵的功效。